419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Reports Second Quarter 2026 Financial Results
Liquidia Corporation Annual Meeting Results; Three Directors Elected
Announces Inclusion in the S&P SmallCap 600® Index
First Quarter 2026 Earnings & Corporate Update
Financial Results, Press Release
Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Free Writing Prospectus